Multiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
|
|
- Elfrieda Goodman
- 8 years ago
- Views:
Transcription
1 Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
2 Multiple Myeloma Untreated Initial Therapy Transplant eligible
3 Multiple Myeloma Untreated N = 470 Resp TTP DVT CR/PR mos % % (med) Thal mg/day + Dex 40mg(day 1-4, , ) Placebo + vs. Dex 40mg (day 1-4, , ) Rajkumar et al., JCO 26:2171, 2008
4 Survival Rate N Survival Probability One-Year Two-Year % % Lenalidomide 25 mg d Dexamethasone 40 mg d 1-4, , vs. Lenalidomide 25 mg d Dexamethasone 40 mg d 1, 8, 15, Rajkumar, et al., ASCO 2008
5 Overall Survival (months) Rd RD Rajkumar, et al., JCO 25:18S, 2007 (ASCO)
6 Multiple Myeloma Untreated N = 48 Response Bortezomib 1.3 mg/m2 % 2/wk x 2 q3 wks CR/NCR 19 + Dexamethasone 40 mg Day of and day after Bortezomib PR 71 if no response Total 90 Jagannath, et al., Blood 108: 238a, 2006
7 Multiple Myeloma Untreated Initial therapy Transplant ineligible CP
8 Multiple Myeloma Untreated age years IFM N= 447 PFS med mos OS med mos MPT (400 mg) x MP x VAD/Mel 100x Facon, et al., Lancet, :1209
9 Multiple Myeloma Untreated age > 75 years IFM 01/01 N= 229 PFS med mos OS med mos MPT (100 mg) d 1-4, 1 q. 6 weeks x M 0.2 mg/kg + P 2 mg/kg d q. 6 weeks x 12 Hulin, et al., Blood 2007, 110:31a
10 San Miguel, et al, ASH 2007 Multiple Myeloma Non-Transplant Candidates Cycles 1-4 Bortezomib 1.3 mg/m2 IV d 1,4,8,11,22,25,29,32 + Melphalan 9 mg/m2 and prednisone 60 mg/m2 d 1-4 Cycles 5-9 Bortezomib 1.3 mg/m2 IV d 1,8,22,29 + Melphalan 9 mg/m2 and prednisone 60 mg/m2 d 1-4 vs. Melphalan 9 mg/m2 and prednisone 60 mg/m2 d 1-4 Nine 6-week cycles of both arms
11 Multiple Myeloma Response to Treatment MPV MP N=336 N=331 p-value M-protein* M-protein* M CR (IF-) 35% 5% < VGPR (>( 90% ÄM-protein) 10% 5% PR 46% 45% *measured in serum or urine by centralized laboratory San Miguel, et al., ASH 2007
12 Multiple Myeloma Grade 3/4 adverse events (%) VMP (n=340) MP (n=337) Gr 3 Gr 4 Gr 3 Gr 4 Neutropenia Thrombocytopenia Anemia GI <1 Peripheral Sensory Neuropathy 13 <1 0 0 Fatigue Asthenia 6 <1 3 0 Pneumonia Herpes Zoster Transfusion (26% vs 35%) and EPO support (34% vs 42%) were somewhat lower on the VMP arm PN resolved or improved in 75% of cases in a median of 64 days DVT was low and the same on both arms (1%) San Miguel, et al., ASH 2007
13 Multiple Myeloma Treatment Relapsed, Refractory
14 Refractory Multiple Myeloma Therapy Vcr Adria Dex (VAD) High-dose corticosteroids Dexamethasone 40 mg d 1 4, 9 12, q mo Thalidomide Bortezomib (Velcade) Lenalidomide (Revlimid)
15 Single-Agent Thalidomide in Recurrent/Refractory Multiple Myeloma Dose Pt RR Study (mg/d) (no.) (%) Singhal, et al * Barlogie, et al ** Grosbois (incl minor response) * >25% Ä in paraprotein ** 2-yr event-free survival and overall survival rates of 20% and 48%, respectively CP
16 Refractory Multiple Myeloma Treatment Bortezomib (VELCADE TM ) (PS-341) n = 193 Response (CR/PR) 35% Duration response 12 mo Richardson et al: NEJM 2003, 348:26.
17 Multiple Myeloma Relapsed Bortezomib, 1.3 mg/m 2 d 1, 4, 8, 11 q 3wks vs. N = 669 Dexamethasone, 40 mg d 1-4; ; TTP mos Survival med mos Richardson, et al., Blood, 2007, 110:3557
18 Multiple Myeloma Relapsed/Refractory Bortezomib, 1.3 mg/m 2 IV d 1, 4, 8, 11 vs. N = 646 Bortezomib, 1.3 mg/m 2 IV d 1, 4, 8, 11 + Doxil 30 mg/m 2 IV d 4 Orlowski et al., JCO, 2007, 25:3892 TTP Survival mos at 15 mos med %
19 Lenalidomide 25 mg d Dexamethasone 40 mg d 1-4, , vs. Placebo d Dexamethasone 40 mg d 1-4, , Multiple Myeloma Relapsed/Refractory 009,010 N = 704 Response CR/PR TTP % Mos (Med) Weber, et al., NEJM, 2007, 357:2133; Dimopoulos, et al., NEJM, 2007, 2 357:2123
20 1.0 Multiple Myeloma n=2,981 Proportion surviving Survival, med 29.9 mo Kumar et al: Blood 111:2516, 2008 Survival, med 44.8 mo Diagnosis during/ before 1996 Diagnosis after 1996 Time from diagnosis (months) P<0.001 CP
21 Proportion surviving Relapse After Autologous Transplant for Multiple Myeloma n=161 Survival, med 30.9 mo Kumar et al: Blood 111:2516, 2008 Exposed to new drugs n=226 Survival, med 14.8 mo No exposure to new drugs n=387 P<0.001 Time from post-asct relapse (months) CP
22 Multiple Myeloma Novel Agents Histone deacetylase inhibitor SAHA Heat Shock protein- 90 inhibitor KOS-953 Tanespimycin VEGF Inhibitors Farnesyl transferase inhibitor Arsenic Trioxide Proteosome inhibitor (oral) FGFR3 inhibitor P 38 MAPK inhibitor PTK787/2K SCH Trisenox NPI-005 Chir-258 Scio-469
23
Treatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationMultiple Myeloma. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1
Multiple Myeloma 8 th Annual Living with Myeloma Conference New Developments in Multiple Myeloma Treatment Scottsdale, AZ March 22, 2014 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville,
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationModern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review
Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review Dr. Kalita Lohit kumar 1, Dr. Gogoi Pabitra Kamar 2, Dr. Sarma Umesh Ch. 3 1 MS, Assistant Professor,
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationMultiple Myeloma. Solving a growing puzzle
Multiple Myeloma Solving a growing puzzle Disclosures Financial I wish. I eat too much. I did ask who the audience would be. Nurses and Doctors Goals 1. Understand the incidence, symptoms, and pathophysiology
More informationMultiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D.
Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm,
More informationOutline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441
European Journal of Haematology ISSN 0902-4441 ORIGINAL ARTICLE Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationMultiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases
Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases Robert Vescio, MD Director Multiple Myeloma & Bone Metastases Program Samuel Oschin Comprehensive Cancer Center Cedars-Sinai
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationWhat's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D.
What's new for the treatment of multiple myeloma and related disorders in 2010? Angela Dispenzieri, M.D. The progress being made for the treatment of multiple myeloma has resulted in a significant prolongation
More informationMULTIPLE MYELOMA Treatment Overview
MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate
More informationMULTIPLE MYELOMA TREATMENT OVERVIEW
MULTIPLE MYELOMA TREATMENT OVERVIEW Sponsored by: This activity is supported by independent educational grants from Genentech BioOncology, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Novartis
More informationFEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD
FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES Updated December, 2011 Authors: Nebu Koshy, MD Binu Nair, MD Gerhard Hildebrandt, MD Reinhold Munker, MD Glenn Mills, MD Mandatory initial tests
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationMultiple Myeloma in HUSM. Dr Azlan Husin HUSM
Multiple Myeloma in HUSM Dr Azlan Husin HUSM Outline Overview Presenting features Progress in myeloma Global HUSM Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation
More informationPersonalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease
/publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of
More informationTherapie des Patienten mit rezidiviertem Multiplem Myelom
DGHO 2014, Hamburg Therapie des Patienten mit rezidiviertem Multiplem Myelom Martin Gramatzki Division for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University of Kiel, Kiel,
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationUnderstanding Revlimid
Understanding Revlimid International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454 TheIMF@myeloma.org
More informationBortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
CLINICAL TRIALS AND OBSERVATIONS Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Antonio Palumbo, 1 Maria Teresa Ambrosini, 1 Giulia Benevolo, 2 Patrizia Pregno, 2 Norbert
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationEffects of bortezomib on the prognosis of the newlydiagnosed multiple myeloma patients with renal impairment
African Journal of Pharmacy and Pharmacology Vol. 6(11), pp. 793-797, 22 March, 2012 Available online at http://www.academicjournals.org/ajpp DOI: 10.5897/AJPP11.530 ISSN 1996-0816 2012 Academic Journals
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationMultiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28
Multiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28 Plasma Cell Disorders Multiple Myeloma Other Disorders Monoclonal gammopathy of undetermined significance (MGUS) Smoldering multiple myeloma (SMM) Solitary
More informationLong-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
ORIGINAL ARTICLE LONG-TERM RESULTS OF REV-DEX THERAPY FOR NEWLY DIAGNOSED MYELOMA Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationRELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY *María-Victoria Mateos, Enrique M. Ocio, Verónica González, Julio Dávila University Hospital of Salamanca/IBSAL, Salamanca, Spain *Correspondence
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationREVLIMID and IMNOVID for Multiple Myeloma
REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.
More informationMultiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee
Hodgkin CML MDS/Other Leuk CLL Neuroblastoma Multiple Myeloma Making Sense of the Report Forms Parameswaran Hari Medical College of Wisconsin Milwaukee Indications for Blood and Marrow Transplantation
More informationIntegrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations
current status in Switzerland and treatment recommendations Christian Taverna a, Mario Bargetzi b, Daniel Betticher c, Jürg Gmür d, Michael Gregor e, Dominik Heim f, Urs Hess g, Nicolas Ketterer h, Erika
More informationHow to treat elderly patients with multiple myeloma: combination of therapy or sequencing
MULTIPLE MYELOMA How to treat elderly patients with multiple myeloma: combination of therapy or sequencing Antonio Palumbo 1 and Francesca Gay 1 1 Divisione di Ematologia dell Università di Torino, Azienda
More informationFARYDAK (Panobinostat) for the Treatment of Patients With Previously Treated Multiple Myeloma
CI-1 FARYDAK (Panobinostat) for the Treatment of Patients With Previously Treated Multiple Myeloma Oncologic Drugs Advisory Committee Meeting November 6, 2014 CI-2 FARYDAK (Panobinostat) for the Treatment
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationFront Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents
Front Line Treatment of Elderly Multiple Myeloma in the Era of Novel Agents The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
More informationREVIEWS. Current treatment landscape for relapsed and/or refractory multiple myeloma
Current treatment landscape for relapsed and/or refractory multiple myeloma Meletios A. Dimopoulos, Paul G. Richardson, Philippe Moreau and Kenneth C. Anderson Abstract Recent developments in the treatment
More informationMULTIPLE MYELOMA. Version Date: February, 2015
MULTIPLE MYELOMA Version Date: February, 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted approaches
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationLenalidomide: A new therapy for multiple myeloma
Cancer Treatment Reviews (2008) 34, 283 291 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv NEW DRUGS Lenalidomide: A new therapy for multiple myeloma Antonio
More informationlenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited
Resubmission: lenalidomide, 5mg, 10mg, 15mg and 25mg hard capsules (Revlimid ) SMC No. (441/08) Celgene Limited 07 March 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationManagement of multiple myeloma: The changing landscape
Blood Reviews (2007) 21, 301 314 www.elsevierhealth.com/journals/blre REVIEW Management of multiple myeloma: The changing landscape Donna E. Reece * Department of Medical Oncology/Hematology, Princess
More informationFocus on the Treatment of Multiple Myeloma
Focus on the Treatment of Multiple Myeloma PRINTER-FRIENDLY VERSION AT CLINICALONCOLOGY.COM SHAJI KUMAR, MD Associate Professor of Medicine Division of Hematology Mayo Clinic Rochester, Minnesota S. VINCENT
More informationHenk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben
More informationOptimizing the Treatment of Transplant- Eligible Patients in Multiple Myeloma
Optimizing the Treatment of Transplant- Eligible Patients in Multiple Myeloma Wednesday, April 10 th, 2013 Chair: Dr. Ade Olujohungbe MD, FRCP, FRCPath Speaker: Dr. Joseph Mikhael MD, MEd, FRCPC, FACP
More informationStem Cell Transplantation for Multiple Myeloma: Current and Future Status
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Stem Cell Transplantation for Multiple Myeloma: Current and Future Status Sergio Giralt 1 1 Memorial Sloan Kettering Cancer Center, New York, NY High-dose
More informationMomentum in Multiple Myeloma Treatment
WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE
More informationMultiple Myeloma Overview. Treatment and challenges.
Multiple Myeloma Overview. Treatment and challenges. Ade Olujohungbe Dip.Haem ( Lond) MD FRCP FRCPath. Associate Professor of Hematology. Cancercare Manitoba Disclosure of Potential for Conflict of Interest
More informationMULTIPLE MYELOMA A new era for an old disease
Emerging trends and recommendations MULTIPLE MYELOMA A new era for an old disease Nizar J. Bahlis, MD and Douglas A. Stewart, MD, FRCPC Top-line summary Multiple myeloma (MM) is the second most common
More information2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper
248 Ivyspring International Publisher Journal of Cancer 2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper Partial Response at Completion of Bortezomib- Thalidomide-Dexamethasone (VTd) Induction
More informationPharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationProtocol for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA Patient information given at each stage following agreed information
More informationIntérêt t clinique de l'identification des
Intérêt t clinique de l'identification des chaînes légères l libres Jean-Fran François Lambert Hematologie - CHUV Healthy 69 yo female Negative past medical history 2/07 acute pulmonary edema Progressive
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationCancer Treatment Reviews
Cancer Treatment Reviews 5 (009) 5 0 Contents lists available at ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT The efficacy of arsenic
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationEvolving Management of Multiple Myeloma: 2015. Todd M. Zimmerman, M.D. Associate Professor of Medicine Section of Hematology/Oncology
Evolving Management of Multiple Myeloma: 2015 Todd M. Zimmerman, M.D. Associate Professor of Medicine Section of Hematology/Oncology MULTIPLE MYELOMA Estimated 24,050 cases and 11,090 deaths in 2014 [1]
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013
pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationAUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? *Patrizia Tosi Hematology Unit, Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy *Correspondence
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationEmerging therapies for the treatment of relapsed or refractory multiple myeloma
European Journal of Haematology REVIEW ARTICLE Emerging therapies for the treatment of relapsed or refractory multiple myeloma Meletios A. Dimopoulos 1, Jesus F. San-Miguel 2, Kenneth C. Anderson 3 1 Department
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationMultiple Myeloma: Overview and Therapeutic Approaches
Multiple Myeloma: Overview and Therapeutic Approaches Presented as a Live Webinar Wednesday, August 14, 2013 and Wednesday, September 11, 2013 Planned and conducted by ASHP Advantage and supported by educational
More informationClinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clin Proc. July 2004;79(7):867-874 www.mayo.edu/proceedings 867
ORIGINAL RELAPSED MULTIPLE ARTICLE MYELOMA Clinical Course of Patients With Relapsed Multiple Myeloma SHAJI K. KUMAR, MD; TERRY M. THERNEAU, PHD; MORIE A. GERTZ, MD; MARTHA Q. LACY, MD; ANGELA DISPENZIERI,
More informationRelapsed Multiple Myeloma
MULTIPLE MYELOMA Relapsed Multiple Myeloma Sagar Lonial 1 1 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA Advances in treatment
More informationBMT CTN PROTOCOL 0702 Version 4.0
A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma BMT CTN PROTOCOL 0702
More informationBackground Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
More informationReview of health-related quality of life data in multiple myeloma patients treated with novel agents
OPEN Leukemia (2013) 27, 1959 1969 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu REVIEW Review of health-related quality of life data in multiple myeloma patients
More informationMULTIPLE MYELOMA TREATMENT REGIMENS (Part 1 of 9)
MULTIPLE MYELOMA TREATMENT S (Part 1 of 9) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationUnderstanding the Immune System in Myeloma
Brian GM Durie Understanding the Immune System in Myeloma Living Well with Myeloma Teleconference Series Thursday, March 19 th 2015 1 The Immune System is Like a Swiss Watch B Cell T Cell Plasma Cell Changing
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationMyeloma: What do We Know? 2015: An Update
Myeloma: What do We Know? 215: An Update Thomas Martin, MD Associate Director, Myeloma Program Clinical Professor of Medicine University of California, San Francisco Plasma Cell Disorders! MGUS! Solitary
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationMULTIPLE MYELOMA. Overview
MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationEvidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE. Bortezomib for the treatment of multiple myeloma patients
Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE Bortezomib for the treatment of multiple myeloma patients Produced by Southampton Health Technology Assessments
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationIJBCP International Journal of Basic & Clinical Pharmacology. Multiple myeloma: the disease and its treatment
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20130302 Review Article Multiple myeloma: the disease and its treatment
More informationDie Behandlung des Multiplen Myeloms innerhalb klinischer Studien
Die Behandlung des Multiplen Myeloms innerhalb klinischer Studien Dr. med. Thilo J. Zander Leitender Arzt Onkologie Luzerner Kantonsspital www.onkologie.ch Proportion surviving OS mit Einführung der Novel
More informationMulticenter, Randomized Trial in Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years (GEM05>65)
Multicenter, Randomized Trial in Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years (GEM05>65) MV Mateos, A Oriol, J Martínez, MT Cibeira, R de Paz, MJ Terol, J García-Laraña, E Bengoechea,
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationOptimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma
Slide 1 Sergio Giralt, MD: Welcome to the webcourse Optimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma. This educational activity is jointly provided by the Potomac Center for
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More information